Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Cardiogenomics Testing Panels Market Poised To Hit $2.78 Billion By 2030 With A 12.3% CAGR
The cardiogenomics testing panels market has experienced significant expansion recently and is projected to grow from $1.55 billion in 2025 to $1.75 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. Contributing factors to this historical expansion include an increasing prevalence of cardiovascular diseases, restricted availability of genetic testing, heightened awareness of inherited cardiac disorders, the widespread use of conventional cardiovascular diagnostic techniques, and the elevated expense associated with initial sequencing technologies.
The cardiogenomics testing panels market is projected to experience significant expansion in the coming years. This market is forecast to reach a value of $2.78 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.3%. This expansion during the forecast period is fueled by advancements in next-generation sequencing (NGS), the incorporation of AI and bioinformatics into diagnostic processes, governmental support for precision medicine, the rising use of multi-gene and whole exome panels, and a heightened need for tailored cardiovascular care. Key developments anticipated during this time involve personalized genetic risk profiling, diagnostic tools powered by AI, the rise of tele-cardiology and remote monitoring, the consolidation of multi-gene panels, and sophisticated bioinformatics platforms.
Get A Free Sample Report With In-Depth Market Insights:
Cardiogenomics Testing Panels Market Expansion Drivers: What’s Shaping Future Growth?
The expanding occurrence of inherited cardiovascular diseases is projected to drive the growth of the cardiogenomics testing panels market moving forward. Inherited cardiovascular diseases (ICDs) are a category of heart and blood vessel disorders that are genetically passed from parents to children. The increase in inherited cardiovascular diseases primarily stems from advancements in genetic testing and diagnostics, which enable more accurate identification of previously undiagnosed conditions. Cardiogenomics testing panels aid in addressing inherited cardiovascular diseases by analyzing a patient’s genes to pinpoint mutations causing hereditary heart conditions, thus facilitating early diagnosis, risk assessment, and customized treatment plans. For instance, in February 2025, according to the Joint Strategic Needs Assessment, a UK-based community health center, in 2023, Blackpool recorded 185 deaths from cardiovascular disease, compared to 178 deaths in 2022. Therefore, the increasing prevalence of inherited cardiovascular diseases is fueling the growth of the cardiogenomics testing panels market.
Cardiogenomics Testing Panels Market Segment Trends And Revenue Contributors
The cardiogenomics testing panels market covered in this report is segmented –
1) By Product Type: Single-Gene Panels, Multi-Gene Panels, Whole Exome Sequencing Panels
2) By Technology: Next-Generation Sequencing, PCR-Based Testing, Microarray, Other Technologies
3) By Application: Inherited Cardiovascular Diseases, Arrhythmias, Cardiomyopathies, Congenital Heart Diseases, Other Appications
4) By End User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By Single-Gene Panels: Ion Channel Gene Panels, Structural Heart Disease Gene Panels, Arrhythmia Gene Panels
2) By Multi-Gene Panels: Cardiomyopathy Panels, Arrhythmia Panels, Congenital Heart Disease Panels
3) By Whole Exome Sequencing Panels: Targeted Cardiovascular Exome Panels, Comprehensive Exome Panels, Research-Oriented Exome Panels
Cardiogenomics Testing Panels Market Company Landscape And Competitive Strategy
Major companies operating in the cardiogenomics testing panels market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Illumina Inc., Actia Group, Invitae Corporation, Fulgent Genetics Inc., GeneDx Inc., Ambry Genetics Corporation, Helix OpCo Inc., Centogene Gmbh, Blueprint Genetics Inc., Strand Life Sciences Pvt. Ltd., Genes2Me Pvt. Ltd., BioAro Inc., GENinCode Plc, Igenomix S.L., Asper Biotech Ltd.
View The Full Cardiogenomics Testing Panels Market Report:
Cardiogenomics Testing Panels Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the cardiogenomics testing panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiogenomics testing panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
